2Fisher RJ, Gaynor ER.Comparison of a standard regimen (CHOP)with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma[J].N Engl J Med, 1993, 328:1002-6.
3Ngeow JY, Quek RH, Ng DC, et al.High SUV uptake on FDGPET/CT predicts for an aggressive B-cell lymphoma in aprospective study of primary FDG-PET/CT staging in lymphoma[J].Ann Oncol, 2009, 20(9):1543-7.
4Weiler-Sagie M, Bushelev O, Epelbaum R, et al.(18)F-FDG avidityin lymphoma readdressed:a study of 766 patients[J].J Nucl Med,2010, 51(1):25-30.
5Spaepen K, Stroobants S, Dupont P, et al.(18) [F]FDG PETmonitoring of tumour response to chemotherapy:does [(18)F]FDGuptake correlate with the viable tumour cell fraction?[J].Eur J NuclMed Mol Imaging, 2003, 30(5):682-8.
6Thomas A, Gingrich RD, Smith BJ, et al.18-Fluoro-deoxyglucosepositron emission tomography report interpretation as predictor ofoutcome in diffuse large B-cell lymphoma including analysis of'indeterminate' reports[J].Leuk Lymphoma, 2010, 51(3):439-46.
7Spaepen K, Stroobants S, Dupont P, et al.Early restaging positronemission tomography with (18)F-fluorodeoxyglucose predictsoutcome in patients with aggressive non-Hodgkin's lymphoma[J].Ann Oncol, 2002, 13(9):1356-63.
9Moskowitz CH, Schoeder H, Teruya-Feldstein JA, et al.Riskadapteddose-dense immunochemotherapy determined by interimFDG-PET in advanced-stage diffuse large B-cell lymphoma[J].JClin Oncol, 2010, 28(11):1896-903.
10Horning SJ, Juweid ME, Sch?der H, et al.Interim positron emissiontomography scans in diffuse large B-cell lymphoma:anIndependent expert nuclear medicine evaluation of the EasternCooperative Oncology Group E3404 study[J].Blood, 2010, 115(4):775-7; quiz 918.
